Buradasınız

Anasayfa » Content

Periton Diyalizi Hastalarında Periton Membran Transportu Beta-2 Mikroglobülinin Periton Klirensini Etkiler mi?

Does Peritoneal Membrane Transport Affect Peritoneal Clearance of Beta 2–Microglobulin in Peritoneal Dialysis Patients?

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2013
DOI: 
DOI 10.5262/tndt.2013.1001.15

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
OBJECTIVE: Our aim in this study was to compare peritoneal clearance of beta 2-microglobulin (B2M) in peritoneal dialysis (PD) patients who had high and low membrane transport status. MA TERIAL and Metho ds: Forty-nine PD patients were included in this study. The patients were divided into two groups according to their peritoneal equilibration test (PET) results; high transport group and low transport group. Serum B2M levels and peritoneal clearance of B2M were compared between the two groups. Res ults : Dialysate B2M level and peritoneal clearance of B2M were higher in the high transporter group than in the low transporter group (5.92 ± 2.62 mg/L vs. 3.42 ± 1.51 mg/L, p: <0.001 and 11.13 ± 2.14 L/week/1.73 m2 vs. 6.41 ± 1.65 L/week/1.73 m2, p: <0.001, respectively). On the other hand, there was no significant difference in serum B2M concentration between the high transport group and the low transport group (24.15 ± 9.10 mg/L vs. 27.35 ± 10.10 mg/L, respectively, P>0.05). Serum B2M concentration was positively correlated with duration of PD (r: 0.518, p: <0.001). ConclusIo n: Although dialysate levels and peritoneal clearance of the middle molecule B2M were significantly higher in high transporters compared to low transporters, there was no significant difference between the two groups in terms of serum B2M concentration.
Bookmark/Search this post with
Abstract (Original Language): 
AMA Ç: Bu çalışmada, yüksek ve düşük geçirgen membran transport özelliğine sahip periton diyalizi (PD) hastalarında beta 2-mikroglobülinin (B2M) periton klirenslerini karşılaştırmayı amaçladık. GEREÇ ve YÖN TEML ER: Kırk dokuz PD hastası çalışmaya alındı. Hastalar periton eşitleme testi (PET) sonuçlarına göre iki gruba ayrıldı; yüksek geçirgen grup ve düşük geçirgen grup. İki grup arasında serum B2M düzeyleri ve B2M’nin periton klirensleri karşılaştırıldı. Bulgular: Diyalizat B2M düzeyi ve B2M’nin periton klirensleri yüksek geçirgen grupta düşük geçirgen gruba kıyasla daha yüksekti (sırasıyla 5,92 ± 2,62 mg/L’ye karşın 3,42 ± 1,51mg/L, p: <0,001 ve 11,13 ± 2,14 L/hafta/1,73 m2 vs. 6,41 ± 1,65, L/hafta/1,73 m2, p: <0,001). Öte yandan yüksek geçirgen grup ile düşük geçirgen grup arasında serum B2M konsantrasyonu açısından anlamlı fark saptanmadı (sırasıyla 24,15 ± 9,10 mg/L’ye karşın 27,35 ± 10,10 mg/L, P>0,05). Serum B2M konsantrasyonu PD süresi ile ilişkiliydi (r: 0,518, p: <0,001). Sonuç: Orta molekül ağırlıklı molekül olan B2M’nin diyalizat düzeyleri ve periton klirensleri yüksek geçirgenlerde düşük geçirgenlere kıyasla anlamlı olarak daha yüksek olmasına rağmen, serum B2M konsantrasyonu açısında iki grup arasında anlamlı fark yoktu.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_22_pp_101-105.pdf
  • 1
101-105
  • Turkish

REFERENCES

References: 

1. Okuno S, Ishimura E, Kohno K, Fujino-Katoh Y, Maeno Y,
Yamakawa T, Inaba M, Nishizawa Y: Serum beta2-microglobulin
level is a significant predictor of mortality in maintenance
haemodialysis patients. Nephrol Dial Transplant 2009; 24: 571-577
2. Karlsson FA: Physical-chemical properties of beta 2-microglobulin.
Immunochemistry 1974; 11: 111-114
3. Orlando RA, Rader K, Authier F, Yamazaki H, Posner BI, Bergeron
JJ, Farquhar MG: Megalin is an endocytic receptor for insulin. J Am
Soc Nephrol 1998; 9: 1759-1766
4. Lonneman G, Koch KM: Beta (2)-microglobulin amyloidosis:
effects of ultrapure dialysate and dialyzer membrane. J Am Soc
Nephrol 2002; 13(suppl1): S72-S77
5. Kazama JJ, Maruyama H, Gejyo F: Reduction of circulating beta2-
microglobulin level for the treatment of dialysis related amyloidosis.
Nephrol Dial Transplant 2001; 16 (Suppl 4): 31-35
6. Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi N,
Takei Y, Kondo T: Amyloid beta2-microglobulin is modified with
N epsilon-(carboxymethyl) lysine in dialysis related amyloidosis.
Kidney Int 1996; 50: 1303-1309
7. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda K, Seo
H: Involvement of beta2-microglobulin modified with advanced
glycation and products in the pathogenesis of hemodialysisassociated
amyloidosis. J Clin Invest 1994; 93: 521-528
8. Assounga A, Canaud B, Flavier JL, Slingeneyer A, Robinet-Lévy
M, Aznar R, Mion C: What does circulating beta2-microglobulin
signify in uremic patients on maintenance dialysis? Nephrologie
1987; 8: 301-306
9. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y: Superior
dialytic clearance of beta2-microglobulin and P-cresol by high-flux
hemodialysis as compared to peritoneal dialysis. Kidney Int 2006;
70: 794-799
10. Bolasco P, Altieri P, Andrulli S, Basile C, Di Filippo S, Feriani M,
Pedrini L, Santoro A, Zoccali C, Sau G, Locatelli F: Convection
versus diffusion in dialysis: An Italian prospective multicentre
study. Nephrol Dial Transplant 2003; 18 Suppl 7:vii50-4; discussion
vii59-62
11. Fry AC, Singh DK, Chandna SM, Farrington K: Relative
importance of residual function and convection in determining
beta2- microglobulin levels in high-flux haemodialysis and on-line
haemodiafiltration. Blood Purif 2007; 25: 295-302
12. Twardowski ZJ: Clinical value of standardized equilibration tests in
CAPD patients. Blood Purif 1989; 7: 95-108
13. National Kidney Foundation: K/DOQI Clinical Practice Guidelines
for peritoneal dialysis Adequacy: Update 2000. Am J Kidney Dis
2001; 37(suppl 1): S65-S136
14. Yamamoto S, Kasai A, Shimada H: High peritoneal clearance of
small molecules did not provide low serum beta2- microglobulin
concentrations in peritoneal dialysis patients. Perit Dial Int 2003;
23: S34-36
15. Chen HC, Guh JY, Lai YH, Tsai JH: Serial changes of serum beta2-
microglobulin in CAPD. Perit Dial Int 1993; 13: 238-239
16. Amici G, Virga G, Da Rin G, Grandesso S, Vianello A, Gatti P, Bocci
C: Serum beta2-microglobulin level and residual renal function in
peritoneal dialysis. Nephron 1993; 65: 469-471
17. McCarthy JT, Williams AW, Johnson WJ: Serum beta2-
microglobulin concentration in dialysis patients: Importance of
intrinsic renal function. J Lab Clin Med 1994; 123: 495-505
18. Yoshida H, Yokoyama K, Munakata K, Maruyama Y, Yamamoto
R, Hanaoka K, Ikeda M, Yamamoto H, Hosoya T: Superior
dialytic clearance of beta2 microglobulin and p-cresol by high-flux
hemodialysis as compared to peritoneal dialysis. Kidney Int 2007;
71: 467; author reply 467-468
19. Brophy DF, Sowinski KM, Kraus MA, Moe SM, Klaunig JE,
Mueller BA: Small and middle molecular weight solute clearance
in nocturnal intermittent peritoneal dialysis. Perit Dial Int 1999; 19:
534-539
20. Kim DJ, Do JH, Huh W, Kim YG, Oh HY: Dissociation between
clearance of small and middle molecules in incremental peritoneal
dialysis. Perit Dial Int 2001: 21: 462-466
21. Blake P, Burkart JM, Churchill DN, Daugirdas J, Depner T,
Hamburger RJ, Hull AR, Korbet SM, Moran J, Nolph KD:
Recommended clinical practices for maximizing peritoneal dialysis
clearances. Perit Dial Int 1996: 16: 448-456
22. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos
DG, Pagé D: Increased peritoneal membrane transport is associated
with decreased patient and technique survival for continuous
peritoneal dialysis patients. The Canada-USA (CANUSA)
Peritoneal Dialysis Study Group. J Am Soc Nephrol 1998; 9: 1285-
1292. (Abstract)

Thank you for copying data from http://www.arastirmax.com